Ann: DIRECTOR: PEB: PEB advises new Director Appointment and Special Meeting

• Release Date: 11/02/16 16:57
• Summary: DIRECTOR: PEB: PEB advises new Director Appointment and Special Meeting
• Price Sensitive: No
• Download Document  5.82KB

					PEB
11/02/2016 16:57
DIRECTOR
NOT PRICE SENSITIVE
REL: 1657 HRS Pacific Edge Limited

DIRECTOR: PEB: PEB advises new Director Appointment and Special Meeting

February 2016

PEB ADVISES NEW DIRECTOR APPOINTMENT AND SPECIAL MEETING

Cancer diagnostic company, Pacific Edge Limited (NZX: PEB) advises that
US-based Director, David Levison, has accepted an invitation to join the
Pacific Edge Limited Board of Directors.

David's appointment is subject to shareholder approval of an increase in
Director remuneration, which will be voted on by shareholders at a Special
Meeting at 11am on Friday 26th February 2016 at the Centre for Innovation in
Dunedin.  A copy of the Notice of Special Meeting is attached.

Pacific Edge's major market is the US Healthcare market and the company has
been actively seeking a US-based and experienced Director to assist in the
rollout of the company's ongoing growth strategy in this region.

David is an experienced and successful executive who has an indepth knowledge
and experience in the US healthcare market. He has been CEO and a Director of
CardioDx, a specialist molecular diagnostic company, since 2004. This is a
similar company to Pacific Edge, with a targeted diagnostic product, high
growth strategy and double digit revenue growth.

David has overseen capital raising of $225m+ of private equity for CardioDx
and was also a Venture Partner in Texas Pacific Ventures, specialising in
healthcare and molecular diagnostic companies. At TRV, he was, among other
roles, Interim CEO of molecular diagnostics company XDx, and Founder of
Cardiodx. Prior to this, he was Founder President and CEO of iScribe (sold to
AdvancePCS) and  President of Oncology Therapeutics Network (sold to
Bristol-Myers Squibb). David holds an MBA from Stanford Graduate School of
Business, and a Bachelor of Economics from Williams College.

Chairman of Pacific Edge, Chris Swann, said: "We are delighted to have
someone of David's experience and calibre join our Board. David is highly
respected within the industry and his hands on experience in building a
successful diagnostics company in the US, as well as his indepth knowledge of
commercial diagnostic products in the US healthcare market, will be of great
value to our company as we look to expand our presence in this region."

The Board unanimously supports David's appointment to the Board. If the
resolution is passed at the Special Meeting, David will be appointed and will
hold office until Pacific Edge's next Annual Shareholders' Meeting at which
time he will offer himself for election by shareholders. The Board has
determined that David Levison is an Independent Director, for the purposes of
NZX Listing Rule 3.3.2.

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5802

OVERVIEW  www.pacificedge.co.nz   www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies. Pacific Edge has
two proprietary, novel, accurate, molecular diagnostic products in-market
providing actionable results, and better detection and management of
urothelial cancer. Cxbladder Detect is available through the company's
dedicated CLIA certified laboratories for customers in New Zealand, Australia
and the USA. Cxbladder Triage is available in New Zealand and Australia.
Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated
being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients with hematuria
and is intended to reduce the need for an expensive and invasive work-up in
patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor  www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,
is a proprietary, non-invasive, molecular diagnostic test that combines
genomic biomarkers measured from a small quantity of a patient's urine, with
patient specific clinical factors to better monitor bladder cancer patients
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires
life-long surveillance. Cxbladder Monitor accurately identifies patients with
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows
that they have a low probability of recurrent urothelial carcinoma. Cxbladder
Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder
cancer.

Refer to www.cxbladder.com for more information.

Notice of Meeting attached in PDF
End CA:00277544 For:PEB    Type:DIRECTOR   Time:2016-02-11 16:57:52